

We claim:

1. A prostate-specific antigen (PSA) derived peptide that is capable of eliciting an immune response comprising a sequence of the Formula I:
- 5 $X_n - X_1 - X - X - X - X - X - X - X_2$
wherein
 $n = 0$ or 1 ;
each X_1 is independently selected from leucine or methionine;
each X_2 is independently selected from valine or leucine; and
- 10 each X is independently selected from any amino acid, and fragments, elongations, analogs or derivatives of the PSA derived peptide.
2. A PSA derived peptide according to claim 1 selected from the group consisting of MWVPVVFL (SEQ ID NO: 1), VLVHPQWVL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3), or a fragment, analog, derivative or elongation of the PSA derived peptide.
- 15
3. A PSA derived peptide according to claim 1 selected from the group consisting of MWVPVVFL (SEQ ID NO: 1), VLVHPQWVL (SEQ ID NO: 2), and KLQCVDLHV (SEQ ID NO: 3).
- 20
4. A fusion protein comprising the PSA peptide as described in claim 1.
- 25
5. A nucleic acid molecule encoding a PSA derived peptide according to claim 1.
6. A nucleic acid molecule encoding a PSA derived peptide according to claim 5 comprising:
- 30 (a) a nucleic acid sequence as shown in any one of SEQ ID NOS:7-9 wherein T can also be U;

Pub No. 40062860

Sub
DB

(b) a nucleic acid sequence that is complementary to a nucleic acid sequence of (a);

(c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b);

5 (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or

(e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

10 7. A nucleic acid molecule encoding a PSA derived peptide according to claim 5 having a sequence selected from the group consisting of: SEQ ID NO:7; SEQ ID NO:8; and SEQ ID NO:9.

8. An expression vector comprising a nucleic acid molecule of claim 5
15 and regulatory sequences suitable for expression of the nucleic acid molecule.

9. A host cell transformed with an expression vector of claim 8.

20 10. A composition for eliciting an immune response in an animal comprising an effective amount of a peptide according to claim 1 in admixture with a suitable diluent or carrier.

11. The composition of claim 10 further comprising an adjuvant.

12. A composition for eliciting an immune response in an animal comprising an effective amount of a nucleic acid according to claim 5 in admixture with a suitable diluent or carrier.

30 13. The composition of claim 12 further comprising an adjuvant.

5 15. A method of eliciting an immune response in an animal comprising administering an effective amount of a fusion protein according to claim 4 to the animal.

17. A method of eliciting an immune response in an animal comprising administering an effective amount of a composition according to claim 10 to the animal.

18. A method of treating cancer comprising administering to an animal an effective amount of a peptide according to claim 1.

20 19. A method of treating cancer comprising administering to an animal an effective amount of a fusion protein according to claim 4.

20. A method of treating cancer comprising administering to an animal an effective amount of a nucleic acid molecule according to claim 5.

21. A method of treating cancer comprising administering to an animal an effective amount of a composition according to claim 10.

22. A method according to claim 18 wherein the cancer is prostate cancer.